Bachem AG is the Swiss operating subsidiary of Bachem Holding AG (SIX: BANB), a publicly listed company headquartered in Bubendorf, Switzerland. Founded in 1971 by Peter Grogg as a peptide-synthesis laboratory, Bachem has been listed on the SIX Swiss Exchange since 1998; its largest shareholder is reported to be Ingro Finanz AG, tied to the founding Grogg family. For fiscal year 2025 it reported group sales of CHF 695.1 million, net income of CHF 148.8 million, and 2,511 full-time-equivalent employees, with market capitalization in the roughly CHF 5.6–5.9 billion range.
Bachem is a contract development and manufacturing organization (CDMO) specializing in peptides and oligonucleotides. Its revenues split across three reported categories: Commercial API (CHF 343.4 million in 2025), CMC Development for clinical-stage programs (CHF 304.0 million), and Research & Specialties such as peptides for diagnostics and cosmetics (CHF 47.7 million). It develops and manufactures active pharmaceutical ingredients from gram to multi-hundred-kilogram scale and sells research biochemicals under the Bachem and Clinalfa brands, with production and R&D sites in Switzerland, elsewhere in Europe, the United States, and Asia.
Litigation posture: an operating company defending, not an NPE. The structured data show one tracked case, with Bachem as defendant (0 as plaintiff). It was named in a U.S. International Trade Commission Section 337 investigation; Bachem has no track record of asserting patents itself in this dataset.
Notable case: BioMarin Pharmaceutical Inc. v. Ascendis Pharma, Inc. et al. (ITC Inv. No. 337-TA-1447, filed 2025). BioMarin alleged infringement of U.S. Reissue Patent No. 48,267 covering C-type natriuretic peptide (CNP) variants, targeting Ascendis's TransCon CNP/navepegritide product. Bachem was added as a respondent effective September 2025 over its role supplying peptide material; it opposed the amendment. The investigation and related global disputes were resolved by a BioMarin–Ascendis settlement announced August 2026, under which Ascendis agreed to royalties and BioMarin moved to dismiss the ITC action.